Executive Series: Bionomics Limited (BNO) CEO, Dr Deborah Rathjen


Online Stockbroker

CommSec's Tom Piotrowski speaks with Bionomics Limited (BNO) CEO, Dr Deborah Rathjen about:

  • BNO’s key programs including the group’s anxiety and Post Traumatic Stress Disorder treatment – BNC210, and cancer treatments BNC101 and BNC105 which have all continued to make recent progress.
  • The progress of BNO’s agreement with Merck & Co. to develop novel drug candidates for its treatment for Alzheimer’s disease which delivered the first milestone payment of US $10 million earlier this year in February.
  • BNO’s cash position which saw the group end 3Q17 with $50m, with net cash of $4.485 million generated for the 9 months to 31 March 2017

1 stock mentioned

Online Stockbroker
Online Stockbroker

CommSec is Australia's leading online broker. CommSec has been committed to providing the best in online trading since 1995. CommSec helps make informed investment decisions with comprehensive market research, free live pricing and powerful...


No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.